Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study

被引:0
|
作者
Souza, LC
Saldiva, PHN
Campa, A [1 ]
机构
[1] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil
[2] Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil
关键词
amphotericin B; lipid emulsion; toxicity;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In previous work acute toxic effects of amphotericin B (AB) were reduced in both in vitro and in vivo tests when AB was associated with a triglyceride-rich emulsion (AB-emulsion). The present paper compares the severity of the histopathological alterations as determined by morphometry produced in the target tissues (kidneys, liver, and lungs) by AB-emulsion with those produced by the conventional formulation AB-deoxycholate (DOC) following subacute AB treatment. No morphological alterations were seen in the spleen and heart following both AB-DOC and AB-emulsion treatment. Although the alterations in the liver, kidneys and lungs are basically the same for both formulations, the intensity of the changes varies considerably. AB-emulsion always caused statistically decreased severity of morphologic alterations, compared to AB-DOC by stereological measurements, for the three treatment regimes of AB-administration, These three treatment regimens consisted of 1 mg AB/kg of body weight every 48 hours for 20 days, 2 mg AB/kg of body weight every 48 hours for 12 days, and 2 mg AB/kg of body weight for 4 consecutive days. Thus, these regimens consisted of total doses varying from 8-12 mg/kg of body weight. Specifically, these morphological changes included proximal and distal tubular edema, inflammation and tubular cell degeneration in the kidney and a moderate inflammation of the portal region in the liver. Vacuolization of hepatocytes only occurred for AB-DOC treatment. In addition, acute interstitial inflammation was observed in the lungs prior to interstitial and alveolar edema. The intensity of the histopathological damage increase with the dose and with the reduction in the time interval between AB administrations. Abnormal serum biochemical parameters were observed for serum urea which was higher for both treated AB-groups, as compared to control, and for iron which was lower for the AB-DOC group. In conclusion, the decreased severity of the morphological alterations in the kidneys, liver, and lungs following subacute treatment with AB-emulsion, as compared to AB-DOC formulation, confirms our previous results consisting of acute toxic effects induced by in vitro and in vivo tests with AB-emulsion treatment.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 50 条
  • [21] Amphotericin B Microemulsion Reduces Toxicity and Maintains the Efficacy as an Antifungal Product
    Damasceno, Bolivar P. G. L.
    Dominici, Victor A.
    Urbano, Isabel A.
    Silva, Joso A.
    Araujo, Ivonete B.
    Santos-Magalhaes, Nereide S.
    Silva, Amanda K. A.
    Medeiros, Aldo C.
    Oliveira, Anselmo G.
    Egito, E. Socrates T.
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2012, 8 (02) : 290 - 300
  • [22] A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients
    Torre, D
    Banfi, G
    Tambini, R
    Speranza, F
    Zeroli, C
    Martegani, R
    Airoldi, M
    Fiori, G
    JOURNAL OF INFECTION, 1998, 37 (01) : 36 - 38
  • [23] Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs
    Nieto, J.
    Alvar, J.
    Rodriguez, C.
    San Andres, M. I.
    San Andres, M. D.
    Gonzalez, F.
    RESEARCH IN VETERINARY SCIENCE, 2018, 117 : 125 - 132
  • [24] Amphotericin B lipid emulsion: A promising alternative formulation to the conventional dosage form
    Pongcharoenkiat, N
    Wirachwong, P
    Burananon, V
    Kraisintu, K
    XIV INTERNATIONAL AIDS CONFERENCE: CLINICAL SCIENCES AND CARE, 2002, : 75 - 79
  • [25] Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia
    Pascual, B
    Ayestaran, A
    Montoro, JB
    Oliveras, J
    Estibalez, A
    Julia, A
    Lopez, A
    ANNALS OF PHARMACOTHERAPY, 1995, 29 (12) : 1197 - 1201
  • [26] SYSTEMIC CLEARANCE OF AMPHOTERICIN-B DELIVERED IN A PARENTERAL LIPID EMULSION TO RATS
    DOLCE, K
    WILLIAMS, A
    KIRSH, R
    KAHN, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 166 - 166
  • [27] Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies
    Laverdière, M
    Habel, F
    Weiss, K
    Delorme, J
    Dubois, G
    Gagnon, N
    Bélanger, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (06) : 910 - 912
  • [28] Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B
    Larabi, M
    Yardley, V
    Loiseau, PM
    Appel, M
    Legrand, P
    Gulik, A
    Bories, C
    Croft, SL
    Barratt, G
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) : 3774 - 3779
  • [29] UNUSUAL LIPID STRUCTURES SELECTIVELY REDUCE THE TOXICITY OF AMPHOTERICIN-B
    JANOFF, AS
    BONI, LT
    POPESCU, MC
    MINCHEY, SR
    CULLIS, PR
    MADDEN, TD
    TARASCHI, T
    GRUNER, SM
    SHYAMSUNDER, E
    TATE, MW
    MENDELSOHN, R
    BONNER, D
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) : 6122 - 6126
  • [30] A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B
    Moreira dos Santos, Delia Chaves
    Silverio de Souza, Marselle Leite
    Teixeira, Eliane Morais
    Alves, Lindicy Leidicy
    Carneiro Vilela, Jose Mario
    Andrade, Margareth
    Carvalho, Maria das Gracas
    Fernandes, Ana Paula
    Miranda Ferreira, Lucas Antonio
    Gontijo Aguiar, Marta Marques
    JOURNAL OF DRUG TARGETING, 2018, 26 (04) : 357 - 364